A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Study Purpose

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:

- Documented diagnosis of multiple myeloma (MM) and measurable disease.

- Documented disease progression during or after their last antimyeloma regimen.

- Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen.

Exclusion Criteria:

- Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis.

- Known central nervous system (CNS) involvement with myeloma.

- Received immunosuppressive medication within the last 14 days of initiating study treatment.

- Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment.

Other protocol-defined inclusion/exclusion criteria apply

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT03989414
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	Phase 1/Phase 2
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Celgene
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Bristol-Myers Squibb
Principal Investigator Affiliation	Bristol-Myers Squibb
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Industry
Overall Status	Recruiting
Countries	Canada, Czechia, Denmark, France, Germany, Greece, Italy, Spain, United States
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Multiple Myeloma
Study Website:	View Trial Website

Arms & Interventions

Arms

Experimental: Cohort A: CC-92480 with bortezomib and dexamethasone

Experimental: Cohort C: CC-92480 with carfilzomib and dexamethasone

Experimental: Cohort H: CC-92480 with elotuzumab and dexamethasone

Experimental: Cohort I: CC-92480 with isatuximab and dexamethasone

Experimental: Cohort D: CC-92480 with bortezomib and dexamethasone

Experimental: Cohort F: CC-92480 with carfilzomib and dexamethasone

Experimental: Cohort J: CC-92480 with elotuzumab and dexamethasone

Experimental: Cohort K: CC-92480 with isatuximab and dexamethasone

Experimental: Cohort G: CC-92480 with bortezomib and dexamethasone

Experimental: Subcohort B1: CC-92480 with daratumumab and dexamethasone

Experimental: Subcohort B2: CC-92480 with daratumumab and dexamethasone

Experimental: Subcohort B3: CC-92480 with daratumumab and dexamethasone

Experimental: Subcohort E1: CC-92480 with daratumumab and dexamethasone

Experimental: Subcohort E2: CC-92480 with daratumumab and dexamethasone

Experimental: Subcohort E3: CC-92480 with daratumumab and dexamethasone